Healio11d
‘Complete eradication’ of B cells drives remission after autoimmune CAR T-cell therapy
A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free ...
Oncology Nurse Advisor3d
FDA Approves New Combined Therapy for Relapsed or Refractory DLBCL
In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.
The Brighterside of News on MSN4d
New CAR-T therapy achieved complete remission in 70% of aggressive cancer patients
CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...
European Medical Journal9d
Study Shows Positive Long-Term Safety of CAR T-Cell Therapy in B-Cell Lymphoma
A study on the long-term safety of CAR T-cell therapy for B-cell lymphoma patients reveals a favourable safety profile with ...
Physician's Weekly4d
Late Adverse Events After CAR T-Cell Therapy in Aggressive B-Cell Lymphoma
The following is a summary of “Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With ...
What Vanderbilt-Ingram Cancer Center's 'sci-fi' therapy means for this grateful TN dad
This cancer-patient dad of three young kids is grateful for a "sci-fi" blood treatment advanced by Vanderbilt and oncologist Dr. Olalekan Oluwole.
KIMSHEALTH gives new lease of life to patient through CAR T-cell therapy
KIMSHEALTH Cancer Centre successfully treats high-grade B-cell lymphoma patient with CAR T-cell therapy, offering new hope.
Healio6d
‘There is a whole other world out there’: Beyond CAR-T therapies for autoimmune diseases
Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...
Targeted Oncology5d
Odronextamab Shows Efficacy in DLBCL Post CAR T-Cell Therapy
Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...